Companies / Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics, Inc.

Nasdaq: BOLTCIK 1641281REDWOOD CITY, CA

Financials · FY2025

Revenue$7.70M
Net income$-33.38M
Total debt—
Cash$12.86M
Diluted EPS$-17.85
Shares outstanding1.9M

Ownership

1.9M shares outstanding · as of Aug 4, 2026
0.19%Insiders
Ownership
Insiders0.19%3,728
Institutions33.31%641,726
Public float66.49%1,280,891

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 5

View all →
Insider% of sharesShares
Quinn William P.CEOPresident, CEO and CFO · Director
0.12%2,313
Nemec SarahSenior VP, Finance and PAO
0.07%1,415
Laporte KathleenDirector
——
Onetto NicoleDirector
——
Yonehiro GrantChief Operating Officer
——

Institutional holders 21

View all →
HolderValue% of shares
Sofinnova Investments, Inc.$753.1K7.15%
Pivotal bioVenture Partners Investment Advisor LLC$517.1K4.91%
Vivo Capital, LLC$396.0K3.76%
Nan Fung Group Holdings Ltd$319.0K3.03%
Renaissance Technologies LLC$312.0K4.01%
T3 Companies, LLC$207.8K1.97%
Pfizer Inc$171.2K1.63%
Board of Trustees of The Leland Stanford Junior University$145.3K1.87%
Geode Capital Management, LLC$116.3K1.49%
Nano Cap New Millennium Growth Fund L P$111.1K1.43%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Dec 5, 2025Quinn William P.
CEO
BuyCommon Stock$576+125
+5.71%
2,313
0.12% of shares
low
Dec 5, 2025Nemec Sarah
Executive
BuyCommon Stock$576+125
+9.69%
1,415
0.07% of shares
low
Jun 10, 2026Onetto Nicole
Director
GrantStock Option (Right to Buy)—+5K
5,000
0.26% of shares
low
Jun 10, 2026Laporte Kathleen
Director
GrantStock Option (Right to Buy)—+5K
5,000
0.26% of shares
low
Jan 28, 2026Quinn William P.
CEO
GrantEmployee Stock Option (Right to Buy)—+20K
20,000
1.04% of shares
low
Jan 28, 2026Yonehiro Grant
Executive
GrantEmployee Stock Option (Right to Buy)—+10K
10,000
0.52% of shares
low
Jan 28, 2026Nemec Sarah
Executive
GrantEmployee Stock Option (Right to Buy)—+8K
8,000
0.42% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Vivo Capital Fund VIII, L.P.Passive13G/A———

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
BOLTCommon StockEquity097702203BBG00N8MY5V9